International pharma Boehringer Ingelheim and prescription digital therapeutics company Click Therapeutics have inked a $500 million-plus deal to jointly develop and commercialize a digital treatment for patients with schizophrenia.
The treatment, referred to as CT-155, will be a mobile app built on Click's proprietary tech platform, the companies said.
Employing cognitive and neurobehavioral...

Photo by Oscar & Associates
This week saw the kickoff of HIMSS19, and the MobiHealthNews staff was on site to interview industry leaders and catch the latest insights from a range of health and tech experts. While the majority of MobiHealthNews' stories and videos from the show floor can be found on our HIMSS19 conference coverage page, there was no shortage of digital product launches, deals and other announcement ...
Medication management and adherence app maker Medisafe has announced a partnership with Boehringer Ingelheim following a successful pilot.
Medisafe will offer a wraparound app experience that incorporates Pradaxa-specific educational information into a special version of its app, which patients will be directed to when they're prescribed the drug.
"Pradaxa is not different than any other...
Following a successful nine-month pilot, Boehringer Ingelheim and HealthPrize Technologies announced that the digital adherence support program RespiPoints will be expanded to any patient who is taking certain Boehringer Ingelheim medications, including some available in the Respimat inhaler.
Launched in 2016, the web- and mobile-based RespiPoints program offers patients a variety of adherence-...
Pharma companies are as excited as anyone about the shift to value-based care and the ways that technology can enable it, but they’re increasingly skeptical about the speed of that change. At Health 2.0 this week in Santa Clara, California, at a panel moderated by Kian Beyzavi, principal investor at KBeyzavi and Associates, several innovation executives at pharmaceuticals talked about value-based...
By way of a contract with UK-based healthcare startup Cera, Uber will help facilitate faster patient care to those in England's National Health Service system by providing on-demand transportation for caregivers and patients between hospitals and homes. Cera originally launched the caregiver-patient matching service in November with a few smaller clinical organizations, and Uber acts as the...
About the author: Naomi Fried, PhD (@NaomiFried), is the CEO of Health Innovation Strategies, which provides digital health strategy and innovation infrastructure consulting to healthcare stakeholders including pharma companies and providers. Her previous positions include the first Chief Innovation Officer at Boston Children’s Hospital, Biogen’s VP of Innovation and External Partnerships, and VP...
Pharmaceutical company Boehringer Ingelheim is partnering with Inovalon, a data analytics company that provides cloud-based platforms to the healthcare industry to facilitate the shift from volume to value-based care, on behalf of Boehringer Ingelheim’s diabetes alliance with Eli Lilly. Leveraging Inovalon’s platform, the partnership will work to support outcomes-based contracting, taking...
Madison, Wisconsin-based Propeller Health has closed a $21.5 million Series C financing round, with new investors 3M Ventures, S.R. One, Limited and Hikma Ventures, plus existing investors Safeguard Scientifics and Social Capital. The funding will be used to further Propeller’s digitally-guided therapy platform.
Propeller’s aim is to simplify management of chronic respiratory diseases like asthma...
The future of pharma is going to involve some major culture shifts for a business that has long been focused on slow development cycles, proprietary molecules, and close-held secrets. That’s the word from representatives from Bayer, Boehringer Ingelheim, Healthware International and BTG, a group that ran the gamut from small to big pharma at yesterday’s Pharma Roundtable onsite at Health 2.0 in...